Nymox Pharmaceutical (NASDAQ:NYMX) Stock Price Crosses Above 200 Day Moving Average of $0.39

Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.39 and traded as high as $0.44. Nymox Pharmaceutical shares last traded at $0.40, with a volume of 11,914 shares.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Nymox Pharmaceutical in a report on Wednesday. They set a “sell” rating on the stock.

Nymox Pharmaceutical Stock Performance

The firm has a market cap of $36.60 million, a P/E ratio of -10.11 and a beta of 0.82. The firm has a 50 day simple moving average of $0.40 and a 200 day simple moving average of $0.39.

Institutional Trading of Nymox Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the company. Simplicity Solutions LLC purchased a new position in shares of Nymox Pharmaceutical during the 1st quarter valued at $27,000. Renaissance Technologies LLC bought a new stake in Nymox Pharmaceutical during the fourth quarter valued at $27,000. Finally, Citigroup Inc. purchased a new position in Nymox Pharmaceutical during the first quarter worth about $137,000. 0.78% of the stock is currently owned by hedge funds and other institutional investors.

Nymox Pharmaceutical Company Profile

(Get Rating)

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe.